LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
32 funds hold it · Insiders net selling
Net selling: insiders sold $20.3M and bought $3K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 4, 2026
Period ending
Sep 26, 2026
Earnings per share
$2.98 expected
Estimates as of Nov 10, 2026
EPS expected
$3.22 to $3.38
Revenue expected
7 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 26, 2026Reported Nov 4, 2026 | $3.09est. $2.98 | +3.55%beat | $982.7MSEC filing | -2.2%from $1.00B |
| Jun 27, 2026Reported Aug 5, 2026 | $3.02est. $2.74 | +10.31%beat | $1.00BSEC filing | -2.7%from $1.03B |
| Mar 28, 2026Reported May 7, 2026 | $2.06est. $1.95 | +5.42%beat | $995.8MSEC filing | +1.2%from $984.2M |
| Dec 31, 2025Reported Feb 18, 2026 | $2.39est. $2.35 | +1.91%beat | $994.2MAlpha Vantage | -0.8%from $1.00B |
| Sep 27, 2025Reported Nov 5, 2025 | $2.43est. $2.32 | +4.74%beat | $1.00BSEC filing | -0.5%from $1.01B |
| Jun 28, 2025Reported Aug 6, 2025 | $3.12est. $2.55 | +22.35%beat | $1.03BSEC filing | +0.6%from $1.03B |
| Mar 29, 2025Reported May 7, 2025 | $2.34est. $2.07 | +13.04%beat | $984.2MSEC filing | -2.7%from $1.01B |
| Dec 31, 2024Reported Feb 19, 2025 | $2.66est. $2.53 | +5.14%beat | $1.00BAlpha Vantage | -1.1%from $1.01B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $994.2M | $995.8M | $1.00B | $982.7M |
| Cost of what it sold | $686.4M | $716.5M | $640.7M | $624.9M |
| Gross profit | $307.9M | $279.3M | $363.4M | $357.9M |
| What it spent | ||||
| Sales and admin | $187.6M | $159.4M | $228.9M | $140.6M |
| Other operating costs | — | — | $14.6M | $14.6M |
| Total operating expenses | $187.6M | $159.4M | $243.5M | $155.2M |
| What was left | ||||
| Operating profit | $120.2M | $119.9M | $119.9M | $202.6M |
| Interest on debt | $23.8M | $26.7M | $30.3M | $28.5M |
| Profit before tax | -$294.1M | -$29.9M | $53.2M | $170.7M |
| Tax | -$17.8M | -$15.1M | $53.9M | -$163.8M |
| Net profit | -$276.6M | -$14.8M | -$1.5M | $333.1M |
| EBITDA | -$192.0M | $64.0M | $150.8M | $270.5M |
This stock is in a strong uptrend.
Trend
Strong uptrend
80 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Charles River Strengthens Global Microbial Solutions Network Through Investments in Manufacturing, Customer Support, and Sustainability
BullishNov 12Clients hold the 1.85M Charles River (CRL) shares underlying Invesco’s reported 3.9% stake.
NeutralNov 10Charles River Laboratories Recent $470 Million Deal an 'Attractive Strategic Addition,' Analyst Says
Leans bullishNov 10Overseas lab services may be sold as Tigermed keeps Frontage's China business
Leans bullishNov 10In Vitro Toxicology Testing - Global Strategic Business Report: Capitalize on the $14B-to-$27.4B Surge as Thermo Fisher Scientific, Merck, Eurofins and Bio-Rad Disrupt Testing by 2032
Leans bullishNov 10Charles River Laboratories to Acquire Frontage Bioanalysis Businesses for Up to $545 Million
BullishNov 9Form 8K Charles River Laboratories International, Inc For: 9 November By Investing.com
NeutralNov 9Is Charles River Laboratories International (CRL) Fully Valued After Raised EPS Guidance?
NeutralNov 936 macro signals shaping CRL right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
